Markets:

Overview

News

Currencies

International

Treasuries

Immatics N.V. - Ordinary Shares (NQ:IMTX)

9.550 -0.280 (-2.85%)

Streaming Delayed Price Updated: 9:30 AM EST, Jan 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Immatics N.V. - Ordinary Shares

< Previous 1 2 3 4 Next >

Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration

May 01, 2023

From https://immatics.com/

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023 ↗

March 31, 2023

Via Benzinga

Immatics Announces Full Year 2022 Financial Results and Corporate Update

March 21, 2023

From https://immatics.com/

Via GlobeNewswire

Immatics Immunotherapy Candidate Shows Confirmed Responses In Different Solid Cancers ↗

October 10, 2022

Via Benzinga

Immatics: Q2 Earnings Insights ↗

August 09, 2022

Immatics (NASDAQ:IMTX) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

First Majestic Silver, Immatics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

March 21, 2023

U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 28, 2022

Via Benzinga

Immatics Announces Third Quarter 2022 Financial Results and Business Update

November 17, 2022

From https://immatics.com/

Via GlobeNewswire

Alphatec Holdings, Immatics And Some Other Big Stocks Moving Higher On Monday ↗

October 10, 2022

U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Monday. Here are some big stocks recording gained in today’s session.

Via Benzinga

Why Immunic Shares Jumped By Around 57%; Here Are 73 Biggest Movers From Yesterday ↗

October 11, 2022

Gainers Applied DNA Sciences, Inc. (NASDAQ: APDN) shares climbed 71% to close at $2.12 on Monday after the company announced it has received its largest single purchase order for LinearDNA™ valued...

Via Benzinga

Why Is Nutex Health (NUTX) Stock on the Move Today? ↗

October 10, 2022

Nutex Health (NUTX) stock is moving on Monday after the healthcare management company released a corporate update to investors.

Via InvestorPlace

Why Applied DNA Sciences Shares Are Trading Higher By Around 65%, Here Are 54 Stocks Moving In Monday's Mid-Day Session ↗

October 10, 2022

Gainers Applied DNA Sciences, Inc. (NASDAQ: APDN) shares jumped 64.5% to $2.03 after the company announced it has received its largest single purchase order for LinearDNA™ valued above the...

Via Benzinga

Ford Stock Slumps 7% on Analyst Downgrade ↗

October 10, 2022

Ford (F) stock is losing traction on Monday after UBS analyst Patrick Hummel hit the automobile company's shares with a downgrade.

Via InvestorPlace

Why Is Immatics (IMTX) Stock Up 7% Today? ↗

October 10, 2022

Immatics (IMTX) stock is climbing higher on Monday after the biopharmaceutical company revealed an underwritten public offering.

Via InvestorPlace

Immatics Announces $110 Million Underwritten Offering of Ordinary Shares

October 10, 2022

From https://immatics.com/

Via GlobeNewswire

Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME

October 10, 2022

From https://immatics.com/

Via GlobeNewswire

Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday ↗

September 13, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.

Via Benzinga

Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session ↗

September 12, 2022

Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.

Via Benzinga

Livent, Amgen And Some Other Big Stocks Moving Lower On Monday ↗

September 12, 2022

U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 23, 2022

Via Benzinga

Why Is CarLotz Higher By More Than 30%: Here Are 28 Stocks Moving Premarket ↗

August 10, 2022

Gainers ObsEva SA (NASDAQ: OBSV) shares rose 33.8% to $0.4080 in pre-market trading. ObsEva recently announced a $31 million debt retirement and $11 million debt refinancing.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 20, 2022

Via Benzinga

July 20, 2022

Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 19, 2022

Via Benzinga

UnitedHealth, Shockwave Lead 5 Healthy Stocks Breaking Out Or Setting Up ↗

June 25, 2022

Shockwave and UnitedHealth lead 5 stocks that are setting up or breaking out.

Via Investor's Business Daily

The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study ↗

June 07, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

June 02, 2022

Via Benzinga

Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs

June 02, 2022

From Bristol Myers Squibb

Via Business Wire

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Immatics Initiates Phase 1 Clinical Trial of IMA401 in Advanced Solid Tumors ↗

May 10, 2022

Immatics N.V. (NASDAQ: IMTX) announced the initiation of a Phase 1 clinical trial of its drug candidate IMA401 for patients with recurrent and/or refractory solid tumors.

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.